Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 31;60(2):250.
doi: 10.3390/medicina60020250.

Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease

Affiliations
Review

Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease

Krishneel Dutt et al. Medicina (Kaunas). .

Abstract

Background: Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, necessitates long-term medical therapy to manage symptoms and prevent complications. Therapeutic drug monitoring (TDM) has emerged as a strategy to optimize treatment efficacy, particularly with anti-tumour necrosis factor (anti-TNF) alpha drugs. This review explores the role of TDM for non-anti-TNF advanced therapies in IBD, focusing on vedolizumab, ustekinumab, tofacitinib, upadacitinib, risankizumab and ozanimod. Methods: The literature search, conducted through OVID (Medline) and PubMed, delves into proactive versus reactive TDM, timing of monitoring and methods for measuring drug levels and anti-drug antibodies. Results: While ustekinumab and vedolizumab exhibit exposure-response relationships, consensus on target levels and the role of TDM adjustments remains elusive. Limited data on risankizumab suggest a dose-dependent response, while for small molecule therapies (janus kinase inhibitors and ozanimod), the absence of real-world data and commercially available TDM tools pose challenges. Conclusion: At present, with the available data, there is a limited role for TDM in non-anti-TNF biologic and small-molecule therapies. This review underscores the need for further research to delineate the utility of TDM in guiding treatment decisions for these agents.

Keywords: JAK inhibitors; filgotinib; inflammatory bowel disease; ozanimod; pharmacokinetics; risankizumab; therapeutic drug monitoring (TDM); tofacitinib; upadacitinib; ustekinumab; vedolizumab.

PubMed Disclaimer

Conflict of interest statement

A. Vasudevan is on the advisory board for Abbvie. K. Dutt has no conflicts of interest to declare.

Similar articles

Cited by

References

    1. Turner D., Ricciuto A., Lewis A., D’Amico F., Dhaliwal J., Griffiths A.M., Bettenworth D., Sandborn W.J., Sands B.E., Reinisch W., et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160:1570–1583. doi: 10.1053/j.gastro.2020.12.031. - DOI - PubMed
    1. Vande Casteele N., Ferrante M., Van Assche G., Ballet V., Compernolle G., Van Steen K., Simoens S., Rutgeerts P., Gils A., Vermeire S. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320–1329.e3. doi: 10.1053/j.gastro.2015.02.031. - DOI - PubMed
    1. Albader F., Golovics P.A., Gonczi L., Bessissow T., Afif W., Lakatos P.L. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J. Gastroenterol. 2021;27:6231–6247. doi: 10.3748/wjg.v27.i37.6231. - DOI - PMC - PubMed
    1. Roblin X., Rinaudo M., Del Tedesco E., Phelip J.M., Genin C., Peyrin-Biroulet L., Paul S. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am. J. Gastroenterol. 2014;109:1250–1256. doi: 10.1038/ajg.2014.146. - DOI - PubMed
    1. Negoescu D.M., Enns E.A., Swanhorst B., Baumgartner B., Campbell J.P., Osterman M.T., Papamichael K., Cheifetz A.S., Vaughn B.P. Proactive vs. Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflamm. Bowel Dis. 2020;26:103–111. doi: 10.1093/ibd/izz113. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources